期刊文献+

A path for diagnosis and therapy of colon cancer: a continuous quality improvement 被引量:1

A path for diagnosis and therapy of colon cancer: a continuous quality improvement
下载PDF
导出
摘要 Objective: Prognosis of colorectal cancer strongly depends on stage at diagnosis, which can be cured in most cases at an early stage. The results were supported by different screening programmes. Few data concerning analysis of different phases of Colorectal Cancer Program were reported in literature. The aim of this study is to analyze "step by step", from a longitudinal type, the Colorectal Cancer Program, active at our Institution, verifying compliance with standards of care.Methods: We compared two different populations during the same period: patients referring to our Clinical Oncology Unit coming from Regional Colorectal Cancer Screening Program and the other population that was not in any Colorectal Cancer Program.Results: Considering patients from the Regional Colorectal Cancer Screening Program(19 patients, corresponding to 24.0% of the general case study), 3(15.8%) were deceased and 16(84.2%) were alive without evidence of the disease(NED). Concerning patients that are not coming from Regional Colorectal Cancer Screening Program(61 patients, corresponding to 76.0% of the general case study), 9(14.8%) were deceased, 43(70.5%) were NED, 8(13.1%) were alive with metastases and 1(1.6%) was lost during follow-up(PFU). Conclusions: On the basis of this experience, we concluded for high-quality care for both populations. Any critical point should be carefully analyzed in order to implement quality of care. Objective: Prognosis of colorectal cancer strongly depends on stage at diagnosis, which can be cured in most cases at an early stage. The results were supported by different screening programmes. Few data concerning analysis of different phases of Colorectal Cancer Program were reported in literature. The aim of this study is to analyze "step by step", from a longitudinal type, the Colorectal Cancer Program, active at our Institution, verifying compliance with standards of care.Methods: We compared two different populations during the same period: patients referring to our Clinical Oncology Unit coming from Regional Colorectal Cancer Screening Program and the other population that was not in any Colorectal Cancer Program.Results: Considering patients from the Regional Colorectal Cancer Screening Program(19 patients, corresponding to 24.0% of the general case study), 3(15.8%) were deceased and 16(84.2%) were alive without evidence of the disease(NED). Concerning patients that are not coming from Regional Colorectal Cancer Screening Program(61 patients, corresponding to 76.0% of the general case study), 9(14.8%) were deceased, 43(70.5%) were NED, 8(13.1%) were alive with metastases and 1(1.6%) was lost during follow-up(PFU). Conclusions: On the basis of this experience, we concluded for high-quality care for both populations. Any critical point should be carefully analyzed in order to implement quality of care.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2014年第6期717-723,共7页 中国癌症研究(英文版)
关键词 Colorectal cancer screening colorectal cancer program quality of care Colorectal cancer screening colorectal cancer program quality of care
  • 相关文献

参考文献22

  • 1Brenner H, Bouvier AM, Foschi R, et al. Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study. IntJ Cancer 2012;131:1649-58.
  • 2Zorzi M, Fedato C, Naldoni C, et al. Screening for colorectal cancer in Italy: 2007 survey. Epidemiol Prev 2009;33:57-74.
  • 3Matarese VG, Feo CV, Lanza G, et al. The first 2 years of colorectal cancer screening in Ferrara, Italy. EurJ Cancer Prev 2011;20:166-8.
  • 4Scally G, Donaldson LJ. The NHS's 50 anniversary. Clinical governance and the drive for quality improvement in the new NHS in England. BMJ 1998;317:61-5.
  • 5Labianca R, Nordlinger B, Beretta GD, et al. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v70-7.
  • 6Van Cntsem E, Nordlinger B, Cervantes A, et al. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Onco12010;21 Suppl 5:v93-7.
  • 7Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin,fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N EnglJ Med 2004;350:2343-51.
  • 8Glen H, CassidyJ. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial. Expert Rev Anticancer Ther 2008;8:547-51.
  • 9Sargent D, Shi Q, Yothers G, et al. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. EurJ Cancer 2011;47:990-6.
  • 10Pezzoli A, Matarese V,, Rubini M, et al. Colorectal cancer screening: results of a 5-year program in asymptomatic subjects at increased risk. Dig Liver Dis 2007;39:33-9.

同被引文献12

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部